The Dose Finding Study of DAOIB Added to tDCS for AD
Status:
Not yet recruiting
Trial end date:
2025-08-19
Target enrollment:
Participant gender:
Summary
This is a 26-week randomized, double-blind, placebo-controlled trial. We will enroll patients
with aMCI or mild AD. All patients will receive 2 weeks of tDCS (5 sessions per week, 10
sessions in total) during the first 2 weeks of the study, and will also be allocated randomly
to either of 4 treatment groups for 24 weeks: (1) Dose A group; (2) Dose B group; (3) Dose C
group; (4) placebo group. We will assess the patients every 8 weeks during the treatment
period (weeks 0, 10, 18, and 26). We hypothesize that augmentation with certain dose of DAOIB
will yield better effect than tDCS alone in improving the cognitive function, global
functioning and quality of life in patients with aMCI or mild AD.